Robert Busch, MD
Endocrinology, Diabetes & Metabolism · Albany, NYNPI 1457358715
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,103,003 of the $2,741,833 with a category attached, or 76.7%. 47 manufacturers reported payments, led by Lilly USA, LLC at 26.5% of the total. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,427 payments — averaging $800.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$726K
- Novo Nordisk$536K
- Sanofi-aventis U.S. LLC$234K
- Bayer$192K
- Boehringer Ingelheim$173K
- Johnson & Johnson$143K
- plus $739K from 41 others
Across 4,480 payments — averaging $1414.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$2.2M
- Eli Lilly$2M
- Sanofi US Services Inc.$385K
- Novartis$320K
- Kowa Research Institute, Inc.$198K
- AstraZeneca$195K
- plus $1M from 22 others
What the payments were for
- Consulting fees$210,4858%
- Speaking & faculty fees$2,103,00377%
- Travel & lodging$370,31314%
- Food & beverage$55,8712%
- Education$2,1020%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$382,296
- TRULICITY$258,074
- Kerendia$190,553
- MOUNJARO$165,519
- Ozempic$160,028
- TZIELD$140,255
- INVOKANA$125,230
- Vascepa$109,225
- RYBELSUS$107,519
- Repatha$107,486
- FARXIGA$98,039
- NEXLIZET$90,466
- NEXLETOL$90,466
- Wegovy$76,733
- Saxenda$75,113
- Korlym$46,821
- STEGLATRO$45,873
- SOLIQUA 100/33$41,934
- REZDIFFRA$36,541
- FreeStyle Libre Pro$28,703
How this compares
$2,741,833 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 457 | $884,306 |
| JardianceEmpagliflozin | 628 | $837,258 |
| MounjaroTirzepatide | 283 | $483,309 |
| TrulicityDulaglutide | 255 | $425,933 |
| Repatha SureclickEvolocumab | 202 | $237,132 |
| FarxigaDapagliflozin Propanediol | 148 | $189,658 |
| KerendiaFinerenone | 93 | $113,980 |
| JanuviaSitagliptin Phosphate | 57 | $86,641 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $79,984 |
| VascepaIcosapent Ethyl | 91 | $70,119 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $69,869 |
| Xigduo XrDapaglifloz Propaned/Metformin | 53 | $63,093 |
| Icosapent Ethyl | 270 | $60,952 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 26 | $59,975 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $53,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Tradjenta, Synjardy | $172,711 | $1,009,770747 claims |
| Novo NordiskOzempic, Wegovy | $536,193 | $914,320468 claims |
| Lilly USA, LLCMounjaro, Trulicity | $725,880 | $909,242538 claims |
| AstraZenecaFarxiga | $112,848 | $189,658148 claims |
| BayerKerendia | $191,537 | $113,98093 claims |
| MerckJanuvia, Janumet | $46,372 | $109,14873 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $233,505 | $45,50526 claims |
| Johnson & JohnsonInvokana | $142,684 | $35,54023 claims |
| AbbVieSynthroid | $13,470 | $33,679344 claims |
| Esperion Therapeutics, Inc.Nexlizet | $91,306 | $21,16022 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $13,244652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Albany
- Gregg GeretyAlbany$345K
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.